elevated pulmonary arterial pressures were not required for enrollment in the Flolan International Randomized Survival Trial (FIRST). 2 However, all patients underwent right-sided heart catheterization, and most subjects ( . 75%) did, in fact, have PH as defi ned by mean pulmonary arterial pressure . 25 mm Hg. This makes it unlikely that epoprostenol is of signifi cant benefi t in patients with systolic heart failure and PH. The same is true for the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) trial. The rationale behind the RELAX trial was to target the pleiotropic (cardiac, vascular, and neurohormonal) effects of phosphodiesterase-5 inhibition on cardiovascular function in patients with heart failure with reduced ejection fraction regardless of the pulmonary pressures. 3 Based on echocardiographic estimates (which are admittedly imprecise), approximately two-thirds of subjects in this trial also had elevated pulmonary arterial systolic pressure ( . 35 mm Hg).
Recently, Bonderman and colleagues 4 reported the results of the Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT). Riociguat, a guanylate cyclase stimulator, is effi cacious in the treatment of pulmonary arterial hypertension and in PH due to chronic thromboembolic disease; it received US Food and Drug Administration approval for these indications in October 2013. LEPHT was a phase 2 trial that examined the hemodynamic effects of riociguat in patients with hemodynamically confi rmed PH due to heart failure with reduced ejection fraction. In this study, riociguat failed to reduce mean pulmonary arterial pressure, and there was no signifi cant improvement in N-terminal pro-brain natriuretic peptide or 6-min walk test distance after 16 weeks of treatment. On a more positive note, subjects receiving riociguat had signifi cantly increased cardiac index and a decrease in the Minnesota Living With Heart Failure score.
To conclude, the clinical trials to date have been disappointing, and the use of PH-specifi c therapies for PH due to LHD should be discouraged outside of the context of clinical trials. We do agree with Dr Guglin that additional, adequately powered, trials looking at subgroups of patients with LHD and a fi xed component of PH are needed. 
Just Because We Can Does Not Mean We Should

A Perspective on Combined Tracheostomy and Percutaneous Endoscopic Gastrostomy Tube Insertion
To the Editor:
We read with interest the article from Yarmus et al 1 in CHEST (August 2013) about the feasibility of percutaneous endoscopic gastrostomy (PEG) tube insertion by interventional pulmonologists. For reasons that are unclear, a combination procedure of PEG and tracheostomy has been advocated by some. In the current work, more than one-half of the patients (n 5 41) underwent a combined procedure. There is some historic observational data on the feasibility of this approach 2 , 3 ; however, effi cacy and safety of this approach has not been previously studied in prospective randomized trials.
Consensus guidelines would suggest that PEG tube insertion be considered for patients who are likely to have a requirement for enteral nutrition of . 30 days. 4 PEG, while safe and reasonably well tolerated, is not a frivolous procedure. Thirty-day mortality after PEG tube insertion has been noted to range between 10% and 26% in some series, largely driven by poor patient selection . 4 , 5 Indeed, in one of the largest published series, a 1-week mortality of 43% was seen in a national confi dential inquiry into patient deaths in the National Health Service, of which 19% of procedures were deemed futile upon expert review. 6 It is with this knowledge that the selection of critically ill patients undergoing tracheostomy as suitable subjects for PEG tube insertion needs to be questioned. By virtue of their complex critical illness, patients undergoing tracheostomy insertion are sick and not optimal subjects. Reported 30-day mortality rates after tracheostomy insertion alone vary but have been reported to be on the order of 30%. 6 -8 For similar reasons, the policy of placing PEG tubes in patients early in the course of their critical illness (as early as 4 days in the current report) and prior to declaration of medical stability is questionable.
In the current series, Yarmus et al 1 reported mortality at 30 days of 11%. The mortality in the group that underwent simultaneous PEG and tracheostomy tube insertion was not reported; we would be interested to see these data.
PEG tubes were removed in 73% of surviving patients within a median of 76 days (range, 24-611 days). This would seem to suggest that PEG tube insertion (and all of its attendant risks) may have been avoided completely in some patients by deferring simultaneous insertion.
Nasogastric feeding tubes are widely regarded as safe and should be the preferred option for short-term nutrition delivery. We feel that the policy of simultaneous PEG and tracheostomy tube insertion should not be advocated until it has been proven to be superior to a watch-and-wait approach in prospective randomized trials.
